NCT05698524View on ClinicalTrials.gov

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 26, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions
Recurrent High Grade GliomaAnaplastic AstrocytomaAnaplastic OligodendrogliomaGlioblastomaGliosarcoma
Interventions
DRUG

PCI 24781

Participants will take PCI-24781/Abexinostat on days 1 - 4, 8 - 11, and 15 - 18 of each 28-day cycle.

DRUG

Temozolomide

Participants will receive temozolomide at a dose of 50 mg/mg2, taken by mouth once daily.

Trial Locations (1)

68198

RECRUITING

University of Nebraska Medical Center, Omaha

All Listed Sponsors
collaborator

Xynomic Pharmaceuticals, Inc.

INDUSTRY

lead

University of Nebraska

OTHER